Angiox (bivalirudin)
- Region
- 🇪🇺 EU
- Active substance
- bivalirudin
- Company
- The Medicines Company UK Ltd
- Status
- Withdrawn
- Therapeutic area
- Acute Coronary Syndrome
- EU approval
- Mon 20 Sep 2004
- Application
- EMEA/H/C/000562
- ATC
- B01AE06
- Official record
- www.ema.europa.eu
Indication
Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary PCI. Angiox is also indicated for the treatment of adult patients with unstable angina / non-ST-segment-elevation myocardial infarction (UA / NSTEMI) planned for urgent or early intervention. Angiox should be administered with aspirin and clopidogrel.
Regulatory milestones
No milestones recorded in the last year.
Follow Angiox
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.